Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Inovio Pharmaceuticals, Inc. Class Action Lawsuit

Core Viewpoint - A class action has been filed against Inovio Pharmaceuticals, Inc. for allegedly misleading investors regarding the approval process of its CELLECTRA device and the INO-3107 Biologics License Application (BLA) [1][2]. Group 1: Allegations and Issues - Robbins LLP is investigating claims that Inovio misled investors by failing to disclose deficiencies in the manufacturing of the CELLECTRA device, which impacted the timeline for submitting the INO-3107 BLA to the FDA [2]. - The complaint states that Inovio was unlikely to submit the INO-3107 BLA by the second half of 2024 due to these manufacturing issues and lacked sufficient information to justify eligibility for FDA accelerated approval [2]. - The overall regulatory and commercial prospects of INO-3107 were allegedly overstated by the company [2]. Group 2: Stock Price Impact - Following a press release on August 8, 2024, revealing a delay in the submission timeline for the INO-3107 BLA to mid-2025, Inovio's stock price fell by $0.27 per share, or 3.1%, closing at $8.44 on August 9, 2024 [3]. - On December 29, 2025, after announcing that the FDA accepted the INO-3107 BLA on a standard review timeline rather than an accelerated one, Inovio's stock price dropped by $0.56 per share, or 24.45%, closing at $1.73 [4]. Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Inovio Pharmaceuticals and can contact Robbins LLP if they wish to serve as lead plaintiff [5]. - Shareholders do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [5].